Találati lista | Tudóstér

001-es BibID:	BIBFORM123332
035-os BibID:	(scopus)85202766719
Első szerző:	Stern, Louisa
Cím:	Efficacy and safety of palliative treatment in patients with autoimmune liver disease-associated hepatocellular carcinoma / Stern Louisa, Schmidt Constantin, Kocheise Lorenz, Joerg Vincent, Casar Christian, Walter Aurélie, Drenth Joost P. H., Papp Maria, Gatselis Nikolaos K., Zachou Kalliopi, Pinter Matthias, Scheiner Bernhard, Vogel Arndt, Kirstein Martha M., Finkelmeier Fabian, Waidmann Oliver, Weinmann Arndt, Milkiewicz Piotr, Thorburn Douglas, Halliday Neil, Lleo Ana, Huber Samuel, Dalekos George N., Lohse Ansgar W., Wege Henning, von Felden Johann, Schulze Kornelius
Dátum:	2024
ISSN:	1665-2681
Megjegyzések:	Introduction and Objectives Autoimmune liver diseases (AILD) are rare causes hepatocellular carcinoma (HCC). and data on the efficacy and tolerability of anti-tumour therapies are scarce. This pan-European study aimed to assess outcomes in AILD-HCC patients treated with tyrosine kinase inhibitors (TKIs) or transarterial chemoembolization (TACE) compared with patients with more common HCC etiologies, including viral, alcoholic or non-alcoholic fatty liver disease. Materials and Methods 107 patients with HCC-AILD (AIH:55; PBC:52) treated at 13 European centres between 1996 and 2020 were included. 65 received TACE and 28 received TKI therapy. 43 (66%) were female (median age 73 years) with HCC tumour stage BCLC A (34%), B (46%), C (9%) or D (11%). For each treatment type, propensity score matching was used to match AILD to non-AILD-HCC on a 1:1 basis, yielding in a final cohort of 130 TACE and 56 TKI patients for comparative analyses of median overall survival (mOS) and treatment tolerability. Results HCC-AILD patients showed comparable mOS to controls for both TACE (19.5 vs 22.1 months, p=0.9) and TKI (15.4 vs 15.1 months, p=0.5). Adverse events were less frequent in AILD-HCC patients than controls (33% vs 62%, p=0.003). For TKIs, there were no significant differences in adverse events (73% vs. 86%, p=0.2) or interruption rates (44% vs. 36%, p=0.7). Conclusions In summary, this study demonstrates comparable mOS for AILD-HCC patients undergoing local and systemic treatments, with better tolerability than HCC of other causes. TKIs remain important therapeutic options for AILD-HCC patients, particularly given their exclusion from recent immunotherapy trials.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk TACE AILD TKI HCC AIH PBC
Megjelenés:	Annals of Hepatology. - 29 : 6 (2024), p. 1-6. -
További szerzők:	Schmidt, Constantin Kocheise, Lorenz Joerg, Vincent Casar, Christian Walter, Aurélie Drenth, Joost P. H. Papp Mária (1975-) (belgyógyász, gasztroenterológus) Gatselis, Nikolaos K. Zachou, Kalliopi Pinter, Matthias Scheiner, Bernhard Vogel, Arndt Kirstein, Martha M. Finkelmeier, Fabian Waidmann, Oliver Weinmann, Arndt Milkiewicz, Piotr Thorburn, Douglas Halliday, Neil Lleo, Ana Huber, Samuel Dalekos, George N. Lohse, Ansgar W. Wege, Henning von Felden, Johann Schulze, Kornelius
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: